NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis $8.65 -0.25 (-2.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.41▼$9.0550-Day Range$6.55▼$8.9352-Week Range$2.35▼$11.55Volume382,192 shsAverage Volume454,499 shsMarket Capitalization$257.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Eliem Therapeutics alerts: Email Address Eliem Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 11 Articles This WeekInsider TradingAcquiring Shares$49.95 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.75 out of 5 starsMedical Sector863rd out of 936 stocksPharmaceutical Preparations Industry405th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Eliem Therapeutics.Read more about Eliem Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.28% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently increased by 98.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELYM. Previous Next 3.0 News and Social Media Coverage News SentimentEliem Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Eliem Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for ELYM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Eliem Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have bought 2,238.07% more of their company's stock than they have sold. Specifically, they have bought $49,952,817.00 in company stock and sold $2,136,494.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions69.76% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eliem Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eliem Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesJuly 24 at 5:24 AM | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 SharesJuly 24 at 5:20 AM | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 60,201 Shares of StockJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 21, 2024 | insidertrades.comValerie Morisset Sells 3,207 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 18, 2024 | insidertrades.comValerie Morisset Sells 42,377 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 12, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 5,931 Shares of StockJuly 12, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 50,000 Shares of StockJuly 10, 2024 | insidertrades.comInsider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 12,342 Shares of StockJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 4, 2024 | insidertrades.comEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 50,000 SharesJuly 2, 2024 | insidertrades.comRa Capital Management, L.P. Acquires 13,008,546 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 25 at 6:42 AM | americanbankingnews.comValerie Morisset Sells 60,201 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) StockJuly 24 at 3:36 AM | finance.yahoo.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 22, 2024 | benzinga.comIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayJuly 19, 2024 | sg.finance.yahoo.comInsider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...July 19, 2024 | finance.yahoo.comEVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)June 28, 2024 | globenewswire.comEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesJune 27, 2024 | globenewswire.comEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.32% Return on Assets-12.95% Debt Debt-to-Equity RatioN/A Current Ratio37.03 Quick Ratio37.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.22Miscellaneous Outstanding Shares29,750,000Free Float28,354,000Market Cap$257.34 million OptionableNot Optionable Beta-0.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsXBiotechNASDAQ:XBITCompugenNASDAQ:CGENSelecta BiosciencesNASDAQ:SELBMarinus PharmaceuticalsNASDAQ:MRNSEnochian BiosciencesNASDAQ:ENOBView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 18,845 shares on 7/26/2024Ownership: 0.063%Valerie MorissetSold 69,005 sharesTotal: $554,110.15 ($8.03/share)Valerie MorissetSold 60,201 sharesTotal: $434,049.21 ($7.21/share)Valerie MorissetSold 3,207 sharesTotal: $22,160.37 ($6.91/share)Valerie MorissetSold 42,377 sharesTotal: $297,062.77 ($7.01/share)View All Insider TransactionsView All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed this year? Eliem Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ELYM stock has increased by 220.4% and is now trading at $8.65. View the best growth stocks for 2024 here. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) announced its earnings results on Wednesday, May, 15th. The company reported ($0.06) earnings per share for the quarter. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Eliem Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.06%). Insiders that own company stock include Ra Capital Management, LP, Valerie Morisset and Emily Pimblett. View institutional ownership trends. How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free elym Stock Alerts